{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:14:11Z","timestamp":1789910051915,"version":"4.0.1"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm & Drug Disp"],"published-print":{"date-parts":[[2017,5]]},"abstract":"Abstract<\/jats:title>Delamanid (OPC\u201067683, Deltyba\u2122, nitro\u2010dihydro\u2010imidazooxazoles derivative) is approved for the treatment of adult pulmonary multidrug\u2010resistant tuberculosis. The absorption, distribution and excretion of delamanid\u2010derived radioactivity were investigated after a single oral administration of 14<\/jats:sup>C\u2013delamanid at 3\u00a0mg\/kg to rats. In both male and female rats, radioactivity in blood and all tissues reached peak levels by 8 or 24\u00a0h post\u2010dose, and thereafter decreased slowly. Radioactivity levels were 3\u2010 to 5\u2010fold higher in lung tissue at time to maximum concentration compared with plasma. In addition, radioactivity was broadly distributed in various tissues, including the central nervous system, eyeball, placenta and fetus, indicating that 14<\/jats:sup>C\u2013delamanid permeated the brain, retinal and placental blood barriers. By 168\u00a0h post\u2010dose, radioactivity in almost all the tissues was higher than that in the plasma. Radioactivity was also transferred into the milk of lactating rats. Approximately 6% and 92% of radioactivity was excreted in the urine and feces, respectively, indicating that the absorbed radioactivity was primarily excreted via the biliary route. No significant differences in the absorption, distribution and excretion of 14<\/jats:sup>C\u2013delamanid were observed between male and female rats. The pharmacokinetic results suggested that delamanid was broadly distributed to the lungs and various tissues for a prolonged duration of time at concentrations expected to effectively target tuberculosis bacteria. These data indicate that delamanid, in addition to its previously demonstrated efficacy in pulmonary tuberculosis, might be an effective therapeutic approach to treating extrapulmonary tuberculosis. Copyright \u00a9 2017 John Wiley & Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.2064","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T21:48:40Z","timestamp":1484603320000},"page":"301-312","source":"Crossref","is-referenced-by-count":24,"title":["Absorption, distribution and excretion of the anti\u2010tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis"],"prefix":"10.1002","volume":"38","author":[{"given":"Masakazu","family":"Shibata","sequence":"first","affiliation":[{"name":"Tokushima Research Institute Otsuka Pharmaceutical Co. Ltd 463\u201010 Kagasuno, Kawauchi\u2010cho Tokushima 771\u20100192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Tokushima Research Institute Otsuka Pharmaceutical Co. Ltd 463\u201010 Kagasuno, Kawauchi\u2010cho Tokushima 771\u20100192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5618-4847","authenticated-orcid":false,"given":"Katsunori","family":"Sasahara","sequence":"additional","affiliation":[{"name":"Tokushima Research Institute Otsuka Pharmaceutical Co. Ltd 463\u201010 Kagasuno, Kawauchi\u2010cho Tokushima 771\u20100192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yoda","sequence":"additional","affiliation":[{"name":"Tokushima Research Institute Otsuka Pharmaceutical Co. Ltd 463\u201010 Kagasuno, Kawauchi\u2010cho Tokushima 771\u20100192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sasabe","sequence":"additional","affiliation":[{"name":"Tokushima Research Institute Otsuka Pharmaceutical Co. Ltd 463\u201010 Kagasuno, Kawauchi\u2010cho Tokushima 771\u20100192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunari","family":"Suzuki","sequence":"additional","affiliation":[{"name":"ADME & Tox. Research Institute Sekisui Medical Co. Ltd 2117 Muramatsu, Tokai\u2010mura, Naka\u2010gun Ibaraki 319\u20101182 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Umehara","sequence":"additional","affiliation":[{"name":"Tokushima Research Institute Otsuka Pharmaceutical Co. Ltd 463\u201010 Kagasuno, Kawauchi\u2010cho Tokushima 771\u20100192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"World Health Organization.Global Tuberculosis Report 2015 20th edn. WHO\/HTM\/TB\/2015.22. WHO: Geneva 2015.http:\/\/apps.who.int\/iris\/bitstream\/10665\/191102\/1\/9789241565059_eng.pdf[20 July 2016]."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073611"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2015.78.2.47"},{"key":"e_1_2_8_5_1","unstructured":"World Health Organization.Guidelines for the programmatic Management of Drug\u2010Resistant Tuberculosis.World Health Organization: Geneva 2008.http:\/\/apps.who.int\/iris\/bitstream\/10665\/43965\/1\/9789241547581_eng.pdf[10 Aug 2016]"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(12)70264\u20105"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060957y"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03014\u201015"},{"key":"e_1_2_8_10_1","unstructured":"OkadaM TanakaT KitaY et al.Poster F\u20101467:In vivoefficacy of novel antituberculous candidate OPC\u201067683 against multi\u2010drug resistantM. tuberculosisusing SCID mice and SCID\u2010PBL\/hu mice. In45th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC. 16\u201319 December 2005."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0616"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00125812"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.064550"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.064527"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4236\/ajac.2015.62009"},{"key":"e_1_2_8_17_1","unstructured":"MiyamotoG ShimokawaY ItoseM KogaT HiraoY KashiyamaE.Poster F\u20101466: unique PK profile of OPC\u201067683 a new potent anti\u2010tuberculous drug. In45th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC 16\u201319 December 2005."}],"container-title":["Biopharmaceutics & Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T06:35:04Z","timestamp":1696574104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/bdd.2064"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2064","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]}}}